Drugs / RBP-6300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01582347 | Mar → Nov 2012 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-28 | Indivior Inc. | Results Indivior | Result of Phase 1 trial of RBP-6300 Buprenorphine Hemiadipate indivior.com ↗
The drug did not achieve the anticipated PK profile in humans to justify proceeding further with this technology. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-28 | Indivior Inc. | Indivior | Result of Phase 1 trial of RBP-6300 Buprenorphine Hemiadipate indivior.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBP-6300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01582347 ↗ |
| Route | Oral | “Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate.” NCT01582347 ↗ |